Literature supports the notion that enhancing CaMKII activity can alleviate neuropathological and neurobehavioural features of AD (e.g., Zeng et al., 2010; Logan et al., 2011; Wang et al., 2013). Here, CAMK2G is linked to Alzheimer disease.